|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||25.79 - 25.79|
|52 Week Range||25.45 - 44.60|
|Beta (3Y Monthly)||0.42|
|PE Ratio (TTM)||21.41|
|Forward Dividend & Yield||0.28 (1.09%)|
|1y Target Est||N/A|
Ipsen and Servier announce initial Phase 1/2 clinical data evaluating liposomal irinotecan (ONIVYDE®) as an investigational first-line treatment for metastatic pancreatic cancer at ESMO 21st World Congress ...
– Treatment emergent adverse events Grade 3 or higher were reported by 20 of 32 patients from the 50/60 dose pooled patient analysis; no patient reported Grade 3 or higher fatigue
ADR: IPSEY), today celebrated the grand opening of the company’s new North American headquarters in Cambridge, Mass. As part of the festivities, more than 115 Ipsen employees took to the community for a Day of Service, supporting and volunteering for nine local charities and non-profit organizations.
Debiopharm (Debiopharm – www.debiopharm.com) and Ipsen (www.ipsen.com) today announced renewal of their Decapeptyl® agreement, which extends and strengthens their strategic partnership through 2034 for the development, manufacturing and distribution of Decapeptyl® across Europe and certain Asian and African markets. Having established their collaboration in the 1980s, this extension represents a long-term commitment to patients, offering the benefits of Decapeptyl® in the treatment of metastatic and non-metastatic patients with locally advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty and endocrine-responsive early-stage breast cancer.
ADR: IPSEY) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a licence update for Dysport® in the treatment of focal spasticity. Dr Stephen Ashford, Consultant Physiotherapist at Northwick Park Hospital, London said "We are delighted by this news and it means the role of the physiotherapist in administration of botulinum toxin for spasticity management is recognised.
The structure's credit enhancement is quantified by the maximum deterioration in property value that the securities are able to withstand under various stress scenarios without causing an increase in the expected loss for various rating levels. Exceptions to this approach exist for the following disclosures, if applicable to jurisdiction: Ancillary Services, Disclosure to rated entity, Disclosure from rated entity.
ADR: IPSEY), a global specialty-driven biopharmaceutical group, today will host an Investor Day in Paris to present a comprehensive corporate update, with a focus on its advancing R&D pipeline. David Meek, Chief Executive Officer of Ipsen stated: “The business momentum of Ipsen is strong, delivering industry-leading top-line growth and investing to build an innovative and sustainable pipeline. “Ipsen currently has five new chemical entities in clinical development, nine significant regulatory submissions planned from 2019 to 2022 and several mid-to-late-stage program readouts in the coming months.
The structure's credit enhancement is quantified by the maximum deterioration in property value that the securities are able to withstand under various stress scenarios without causing an increase in the expected loss for various rating levels. For provisional ratings, this announcement provides certain regulatory disclosures in relation to the provisional rating assigned, and in relation to a definitive rating that may be assigned subsequent to the final issuance of the debt, in each case where the transaction structure and terms have not changed prior to the assignment of the definitive rating in a manner that would have affected the rating.
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But on a lighter note, a good company can see its share price rise well over 100%. For example, th...
ADR: IPSEY) and Clementia Pharmaceuticals (CMTA) today announced the closing of Ipsen’s acquisition of Clementia following approval of the arrangement by Clementia shareholders and the Quebec Superior Court. Pursuant to the arrangement, Clementia shareholders will receive US$25.00 per share in cash upfront and one contingent value right (CVR) per share entitling them to receive US$6.00 per CVR upon the U.S. Food and Drug Administration's (FDA) acceptance of the regulatory filing for palovarotene for the treatment of multiple osteochondromas (MO).
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it prac...
ADR: IPSEY) announced today that its 2018 Registration Document has been filed with the French “Autorité des Marchés Financiers” (AMF) on 26 March 2019 and registered under the number D.19-0205. Copies are also available at Ipsen’s headquarters – 65 quai Georges Gorse, 92100 Boulogne-Billancourt – France. Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care.
ADR: IPSEY) today announced that they are looking forward to revealing 17 presentations that detail their research into neuroendocrine tumors (NETs) at the 16th European Neuroendocrine Tumor Society (ENETS) Annual Conference, which is taking place in Barcelona, Spain between 6th-8th March 2019. Input from patients and their caregivers, as well as nurses and other healthcare professionals, was used to design a new pre-filled syringe1 that was submitted to the European Union as a type II variation via a work-sharing procedure with HPRA (Ireland) as the reference country. “It is our mission to ensure patients continue to receive optimized care as they navigate the challenges of living with NETs and acromegaly,” said Sotirios Stergiopoulos, Chief Medical Officer at Ipsen.